HMGB1 and non-small cell lung carcinoma: Several previous IHC studies have reported associations between high HMGB1 immunostaining and unfavorable tumor phenotype or poor prognosis in non-small-cell lung cancer [34], cervical cancer [35], squamous cell carcinoma of the esophagus [36], squamous cell carcinoma of the larynx [37], urothelial carcinoma of the bladder [38], breast cancer [39], as well as colorectal [27] and gastric adenocarcinoma [40,41,42].